RaQualia PharmaTSE:4579 -2.70%57 Quick Ratio is 6.01 as of Mar. 2026, which is 47% below its 10-year median of 11.28. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, RaQualia Pharma ranks better than 64.99% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. RaQualia Pharma's quick ratio for the quarter that ended in Mar. 2026 was 6.01.
RaQualia Pharma has a quick ratio of 6.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for RaQualia Pharma's Quick Ratio or its related term are showing as below:
TSE:4579'
s Quick Ratio Range Over the Past 10 Years
Min: 3.52 Med: 11.28 Max: 22.3
Current: 6.01
During the past 13 years, RaQualia Pharma's highest Quick Ratio was 22.30. The lowest was 3.52. And the median was 11.28.
TSE:4579's Quick Ratio is ranked better than 64.99% of 1408
companies
in the Biotechnology industry
Industry Median: 3.6
vs TSE:4579: 6.01
RaQualia Pharma (TSE:4579) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
RaQualia Pharma Quick Ratio Related Terms
RaQualia Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, RaQualia Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
RaQualia Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Quick Ratio of 6.01 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RaQualia Pharma and its competitors. This is 47% below median its historical median of 11.28. Over the past decade, RaQualia Pharma's Quick Ratio has ranged from 3.52 to 22.30. According to the industry distribution chart, RaQualia Pharma ranks #493 out of 1408 companies in the Biotechnology industry, placing it in the top 35%.
Is RaQualia Pharma's Quick Ratio too high?
RaQualia Pharma's current Quick Ratio of 6.01 is 47% below median its 10-year median of 11.28. Over the past 10 years, this metric has ranged from a low of 3.52 to a high of 22.30. The Biotechnology industry median Quick Ratio is 3.60. RaQualia Pharma's value of 6.01 is 66.9% above this industry median. Based on the distribution chart, RaQualia Pharma ranks #493 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #493 out of 1408 companies for Quick Ratio. This puts RaQualia Pharma in the upper half of its industry. The industry median Quick Ratio is 3.60. RaQualia Pharma's value of 6.01 is 66.9% above this benchmark. Historically, RaQualia Pharma's own Quick Ratio has ranged from 3.52 to 22.30 over the past decade. While the company's 10-year median is 11.28 vs. the industry median of 3.60, RaQualia Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Quick Ratio of 6.01 is 66.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Quick Ratio is 6.01, which is 47% below median its own 10-year median of 11.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Quick Ratio is 6.01, which is 47% below median its 10-year median of 11.28 and 66.9% above the Biotechnology industry median of 3.60. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Quick Ratio is 6.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Quick Ratio: 6.01 (47% below median its 10-year median of 11.28)
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
Industry Position: 66.9% above the Biotechnology median (#493 of 1408)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
